President & CEO, MaxCyte
Douglas Doerfler has over 30 years experience in the discovery, development and international financing and commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999. Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global businesses, mergers and acquisitions and public offerings. Mr. Doerfler plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry Organization’s Board of Directors, and Co-Chairs BIO’s Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology Counciland the Alliance for Regenerative Medicine, and serves on the Governing Board of Shady Grove Hospital. He is also Chairman of MDBio. Doug received his B.S. in Finance from the University of Baltimore School of Business and a certificate in Industrial Relations.